The CD38 molecule is highly expressed on the surface of multiple myeloma cells; therefore, it is a target of certain novel monoclonal antibodies used in the treatment of multiple myeloma.
Mutations in BRCA1 are targets in breast cancer, ovarian cancer, and prostate cancer. The CD20 molecule is a target for B-cell malignant tumors, as well as for leukemias and lymphomas, and the CD30 molecule is a target for some lymphomas.
Learn more about monoclonal antibodies in multiple myeloma.
Medscape © 2021 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Joshua Richter. Fast Five Quiz: Multiple Myeloma Management - Medscape - May 13, 2021.
Comments